New Research on Genprex, Inc. (GNPX-NASDAQ)

Posted by Karen Goldfarb

June 23, 2022 at 7:58 PM

An Executive Informational Overview (EIO) is now available on Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The 62-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Genprex, Inc. Initiation Report

Read More

Topics: cancer,  REQORSA, genprex, diabetes, gene therapy, non-small cell lung cancer, small-cell lung cancer

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic